Safety and efficacy of template combined with CT-guided radioactive Iodine-125 seeds implantation in the treatment of thoracic malignancies: a single-center prospective phase I clinical trial

Dosimetry Study and Clinical Observation of Real-time CT-guided Radioactive Iodine-125 Seeds implantation in the Treatment of Recurrent Lung Cancer after Radiotherapy

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800019945

Enrollment

Unknown

Registered

2018-12-09

Start date

2015-03-01

Completion date

Unknown

Last updated

2018-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thoracic malignancies

Interventions

Case series:radioactive Iodine-125 seeds implantation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Recurrence after surgery, radiotherapy and chemotherapy, tumor diameter less than 10 cm; 2. Pathological diagnosis is definite; 3. There is a suitable puncture path; 4. KPS>70 score.

Exclusion criteria

Exclusion criteria: 1. Infectious and radiative inflammation around the lesion which is not well controlled; 2. Severe bleeding tendency, thrombocytopenia and coagulation dysfunction; 3. Systemic lesions are widespread and uncontrolled; 4. Severe liver, kidney, heart, lung and brain dysfunction; 5. bleeding tendency.

Design outcomes

Primary

Measure	Time frame
Local control rate;Toxicity;	—

Secondary

Measure	Time frame
Overall survival;	—

Countries

China

Contacts

Public ContactJunjie Wang

Peking University Third Hospital

junjiewang_edu@sina.cn+86 13701076310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026